Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Moderna's Cancer Vaccine Worked -- and the Stock Plunged Anyway. Here's What Investors Are Missing.
Moderna (NASDAQ:MRNA) Stock Price Crosses Below 50-Day Moving Average After Insider Selling - Stock Observer
Insider Selling: Moderna (NASDAQ:MRNA) President Sells 39,160 Shares of Company Stock
Best Biotech Stocks To Consider - November 18th - Zolmax
Moderna (NASDAQ:MRNA) Stock: Insider Stephen Hoge Sells 39,215 Shares - Stock Observer
Promising Healthcare Stocks To Research - November 18th - Stock Observer
Moderna Targets Year-End Cancer Therapy Filing, Sees Multibillion-Dollar Opportunity
Invesco S&P 500 Equal Weight (RSP) Buys $0.7 Million More PTC on Nov. 16
Promising Biotech Stocks To Follow Today - November 17th - Stock Observer
What iShares Biotechnology ETF (IBB) Bought: Gilead Leads on Nov. 13
Moderna (MRNA) Lifts 2026 Guidance, Is It Fully Priced?
Moderna (NASDAQ:MRNA) Given New $200.00 Price Target at Morgan Stanley - Daily Political
Moderna, Inc. (NASDAQ:MRNA) Stock Has Average Price Target of $113.75 According to Brokerages - Daily Political
Moderna (NASDAQ:MRNA) Stock Falls 3.6% - What's Next?
Top Healthcare Stocks To Watch Now - November 15th - Daily Political
Moderna Is Up Over 600% This Year. Here's What Jim Cramer Learned in His Exclusive - 24/7 Wall St.
Moderna, Delta stock pullbacks: Josh Brown says watch these levels
Healthcare Stocks To Follow Today - November 16th - Stock Observer
What Invesco S&P 500 Equal Weight ETF (RSP) Bought: Moderna Leads on Nov. 12
84,445 Moderna, Inc. $MRNA Shares Purchased by Russell Investments Group Ltd. - Daily Political
The Call Moderna Bulls Got Right Before An 802% Rally
Bank of America Securities Reaffirms Their Sell Rating on Novavax (NVAX)
Aberdeen Group plc Buys 1,039,311 Shares of Moderna, Inc. $MRNA
Moderna, Inc. (NASDAQ:MRNA) Stock Has Average Target Price of $113.75
Moderna (NASDAQ:MRNA) Stock Price Down 3.4% - Time to Sell?
The Single Most Important Metric For Moderna Stock
The science of vaccines is rapidly advancing - despite the anti-vax movement | Morningstar
While AI hogged the headlines, 1 overlooked sector beat the S&P 500 - and its top stock is up 700%+ this year - AOL
What Invesco S&P 500 Equal Weight ETF (RSP) Sold: Moderna Leads on Nov. 11
Moderna, Inc. $MRNA Stock Position Lifted by Retirement Systems of Alabama - Daily Political
GSK (LSE:GSK) Settles Key Vaccine Patent Case And Wins Broad Europe Injunction
Moderna: Analyst Day Reveals Increased Oncology Investment and Manufacturing Readiness | Morningstar
Moderna Targets 2027 Cancer Therapy Launch, Raises 2026 Revenue Growth Outlook
Biotech Stocks To Research - November 10th - Zolmax
Healthcare Stocks To Watch Today - November 12th - Markets Daily
Why Moderna Stock Dropped on Thursday
Moderna Raises 2026 Revenue Growth Forecast to 15%-25% and Reports Progress in Cancer Vaccine Development
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Moderna, Inc. (NASDAQ:MRNA)
The world's most sophisticated drug companies are putting billions into vaccines - despite the political environment | Morningstar
40,297 Moderna, Inc. $MRNA Shares Sold by New York Life Investment Management LLC - Stock Observer
AI Deep Integration in Organizations: Should CHRO and CTO Roles Merge?
Moderna CEO: Laying ground for cancer vaccine to sell more than Keytruda
FDA nod takes China-origin pimicotinib into US TGCT fight
FY2026 EPS Estimate for Moderna Boosted by Analyst
Gryphon Financial Partners LLC Purchases 2,439 Shares of Moderna, Inc. $MRNA - Stock Observer
8,175 Moderna, Inc. $MRNA Shares Sold by Montaka Global Pty Ltd - Daily Political
Moderna (NASDAQ:MRNA) Shares Down 6.8% - Time to Sell?
Moderna (MRNA) vs. Its Rivals Head to Head Comparison - Stock Observer
FY2029 EPS Estimate for Moderna Cut by Analyst
What Invesco S&P 500 Equal Weight ETF (RSP) Bought: Moderna Leads on Nov. 6
Pictet Asset Management Holding SA Sells 156,247 Shares of Moderna, Inc. $MRNA
Fulcrum Asset Management LLP Purchases 18,554 Shares of Moderna, Inc. $MRNA
Why Did U, MRNA, ABNB Stocks Surge To 52-Week Highs Today?
Company Merged HR and IT Departments: Key Outcomes and Impacts Explained
Moderna (NASDAQ:MRNA) Shares Up 5.8% Following Strong Earnings
Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a Buy - AOL
Is Moderna (MRNA) Priced For Too Much Sales Growth?
Moderna (MRNA) Stock Fair Value Rises After Intismeran Data And Q3 Beat
MRNA Maintained by Goldman Sachs -- Price Target Raised to $195
MRNA Reiterated by Piper Sandler -- Price Target Raised to $305
MRNA support and resistance levels to watch
Moderna Earnings: Raising Fair Value Estimate as Steadying Demand for Respiratory Vaccines Supports Strong Quarter | Morningstar
Best Healthcare Stocks To Keep An Eye On - November 9th - Stock Observer
The Goldman Sachs Group Issues Positive Forecast for Moderna (NASDAQ:MRNA) Stock Price - Daily Political
Why Did MRNA, XERS, VIR Stocks Surge To 52-Week Highs Last Week?
Moderna Stock Is Up 5.3% What's Changed After Profit Return - Simply Wall St News
Moderna (MRNA) Shares Rally After Q3 2026 Beat, Raising Full-Yea
Moderna's cost cuts turn a 29% revenue jump into a $162 million profit
Moderna, Inc. $MRNA Stock Holdings Lifted by Candriam S.C.A. - Zolmax
Moderna, Inc. $MRNA Stock Bought by Candriam S.C.A.
Promising Biotech Stocks To Watch Now - November 5th - Daily Political
Sumitomo Mitsui Trust Group Inc. Purchases 38,833 Shares of Moderna, Inc. $MRNA
Best Biotech Stocks Worth Watching - November 7th - Stock Observer
Moderna, Inc. $MRNA Shares Acquired by Sumitomo Mitsui Trust Group Inc. - Stock Observer
Moderna (NASDAQ:MRNA) Stock Falls 6.5% - Here's Why - Daily Political
Moderna (NASDAQ:MRNA) Stock Price Up 13.1% - Here's Why
Moderna (NASDAQ:MRNA) Posts Earnings Results, Beats Expectations By $1.48 EPS
Moderna (MRNA) Stock Climbs As Q3 Earnings Mark Return To Profit
Bernstein's Courtney Breen talks what is driving Moderna's post-earnings gains
Moderna (NASDAQ:MRNA) Shares Climb 5.3% on Earnings Beat
Moderna Inc (MRNA) Q3 2026 Earnings Call Highlights: Revenue Surges 29% as Guidance Raised and ...
Moderna Earnings: Steadying Demand for Respiratory Vaccines Supports Strong Quarter | Morningstar
Moderna's Impressive Intismeran Data in Melanoma Could Form Foundation of Oncology Portfolio | Morningstar
Moderna earnings analysis: questions answered and next catalysts
What Moderna (MRNA) Said on Its Q3 Earnings Call
Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher
Moderna (MRNA) Stock: Rally 7.38% as $1.3B Revenue and Positive Cancer Trial Results Boost Optimism
Moderna raises its revenue outlook - but all eyes are on what happens next with its cancer vaccine | Morningstar
Moderna shares jump as earnings beat prompts higher 2026 sales outlook
Moderna Returns To Q3 Profit; Raises FY26 Outlook On Vaccine Sales And Pipeline Progress
Dow Jones Top Company Headlines at 9 AM ET: Tesla's Polarizing Cybertruck to Wind Down Production Amid Slow Sales | Moderna ... | Morningstar
Latest news
Show more
Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty
September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations
Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge
